B2B Manufacturing ModelA B2B manufacturing model supplying industrial buyers supports recurring, contract-driven demand and higher customer stickiness than retail channels. Over a multi-month horizon this can stabilize revenue if production utilization and long-term supply relationships are sustained.

Pharma Supply-chain ExposureOperating in the specialty and generic drug supply chain creates structural demand for biochemical inputs driven by pharmaceutical manufacturing needs. Regulatory and technical barriers to entry support durable demand characteristics for qualified suppliers over months.

Existing Manufacturing CapacityAn existing operational footprint and a workforce of 191 indicate tangible production capacity and institutional knowledge. Retained manufacturing assets and personnel reduce time and capex required to ramp output, aiding recovery if demand or utilization improves.

Bears Say

Highly Leveraged Balance SheetNegative shareholders' equity and high leverage create structural solvency and refinancing risk. This limits access to fresh capital, raises lender and supplier scrutiny, and constrains management's ability to invest or execute turnaround plans over the coming months.

Persistent Negative Cash FlowSustained negative operating and free cash flows indicate poor cash conversion and an inability to self-fund working capital or capex. Over 2-6 months this forces reliance on external financing and increases risk of operational disruptions or curtailed investment.

Consistent Losses And Revenue DeclineOngoing negative net income, deeply negative EBIT margins, and steep revenue decline signal structural operational inefficiencies and loss of scale. Persistent margin pressure undermines competitiveness and makes it harder to cover fixed costs or invest in product and process improvements.

Krebs Biochemicals & Industries Ltd. News

Krebs Biochemicals Board Clears Q3 FY2025 Unaudited Results After Clean Review

Krebs Biochemicals & Industries Ltd. ( ($IN:KREBSBIO) ) has shared an update. Krebs Biochemicals & Industries Ltd. announced...

21d ago

Krebs Biochemicals to Shut Trading Window Ahead of Q3 Results

Krebs Biochemicals & Industries Ltd. ( ($IN:KREBSBIO) ) just unveiled an update. Krebs Biochemicals & Industries Ltd. has...

2M ago

KREBSBIO FAQ

What was Krebs Biochemicals & Industries Ltd.’s price range in the past 12 months?

Krebs Biochemicals & Industries Ltd. lowest stock price was ₹51.00 and its highest was ₹113.90 in the past 12 months.

What is Krebs Biochemicals & Industries Ltd.’s market cap?

Krebs Biochemicals & Industries Ltd.’s market cap is ₹1.25B.

When is Krebs Biochemicals & Industries Ltd.’s upcoming earnings report date?

Krebs Biochemicals & Industries Ltd.’s upcoming earnings report date is May 26, 2026 which is in 85 days.

How were Krebs Biochemicals & Industries Ltd.’s earnings last quarter?

Krebs Biochemicals & Industries Ltd. released its earnings results on Feb 09, 2026. The company reported -₹1.45 earnings per share for the quarter, missing the consensus estimate of N/A by -₹1.45.

Is Krebs Biochemicals & Industries Ltd. overvalued?

According to Wall Street analysts Krebs Biochemicals & Industries Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Krebs Biochemicals & Industries Ltd. pay dividends?

Krebs Biochemicals & Industries Ltd. does not currently pay dividends.

What is Krebs Biochemicals & Industries Ltd.’s EPS estimate?

Krebs Biochemicals & Industries Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Krebs Biochemicals & Industries Ltd. have?

Krebs Biochemicals & Industries Ltd. has 21,560,587 shares outstanding.

What happened to Krebs Biochemicals & Industries Ltd.’s price movement after its last earnings report?

Krebs Biochemicals & Industries Ltd. reported an EPS of -₹1.45 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.018%.

Which hedge fund is a major shareholder of Krebs Biochemicals & Industries Ltd.?

Currently, no hedge funds are holding shares in IN:KREBSBIO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Krebs Biochemicals & Industries Ltd.

Krebs Biochemicals & Industries Limited manufactures and sells active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry fields. Its products, such as androstenedione, lovastatin, and simvastatin for anti-cholesterol and steroid intermediate applications. The company is also developing various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was incorporated in 1991 and is headquartered in Hyderabad, India.